Non-obvious effects of montelukast – leukotriene receptor blocker: frigoprotective and anticonvulsant properties
Open Access
- 18 June 2021
- journal article
- research article
- Published by Dnipro State Medical University in Medicni perspektivi
- Vol. 26 (2), 19-25
- https://doi.org/10.26641/2307-0404.2021.2.234486
Abstract
The participation of arachidonic acid metabolism products – prostaglandins and leukotrienes – in the process of inflammation is a common pathogenetic link of cold injury and epilepsy. Montelukast is widely used for the treatment of bronchial asthma and allergic rhinitis as a leukotriene receptor blocker. However, the mechanism of action of the drug suggests a wider range of its pharmacological properties and the corresponding scope of application. This study is aimed to determine the effectiveness of montelukast as a potential frigoprotective and anticonvulsant drug. Experiments were performed on 73 white mice weighing 20-22 g on models of acute general cooling and pentylenetetrazol convulsions. Frigoprotective properties were studied at a temperature of –18°C, recording the lifetime. Montelukast ("Singular", 2 mg/kg), acetylsalicylic acid ("Aspirin", 50 mg/kg), celecoxib ("Celebrex", 74 mg/kg), diclofenac sodium ("Voltaren", 14 mg/kg) were administered intragastrically as a suspension in a prophylactic mode, 30 minutes before the cold injury. In the study of anticonvulsant activity, montelukast ("Singular", 4 mg/kg) and sodium valproate ("Depakin", 300 mg/kg) were administered intragastrically 30 minutes before stimulating convulsions by subcutaneous administration of pentylenetetrazole (90 mg/kg). The latent period of convulsions, the number of convulsions per 1 animal, % of mice with clonic and tonic paroxysms, the severity of convulsions in points, the duration of the convulsive period, the lifetime of animals and lethality were recorded for an hour. On the model of acute general cooling, montelukast showed a dose-dependent frigoprotective effect at a dose of 2 mg/kg surpassing drugs with proven frigoprotective properties – acetylsalicylic acid and celecoxib. On the model of pentylenetetrazole-induced convulsions, montelukast statistically significantly reduced the integral indicator of anticonvulsant activity – lethality – by 2.57 times. Thus, the experiment proved the significant role of leukotrienes in the pathogenesis of cold injury and epilepsy and justified the feasibility of further study of the frigoprotective and anticonvulsant properties of montelukast – leukotriene receptor blocker a drug as for adjuvant therapy, especially when these pathologies are combined with bronchial asthma and allergic rhinitis.Keywords
This publication has 9 references indexed in Scilit:
- The Role of Leukotrienes Inhibitors in the Management of Chronic Inflammatory DiseasesRecent Patents on Inflammation & Allergy Drug Discovery, 2020
- Thiazole-Bearing 4-Thiazolidinones as New Anticonvulsant AgentsScientia Pharmaceutica, 2020
- Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Frostbite: 2019 UpdateWilderness & Environmental Medicine, 2019
- Neural stimulation systems for the control of refractory epilepsy: a reviewJournal of NeuroEngineering and Rehabilitation, 2019
- Characterization of cysteinyl leukotriene-related receptors and their interactions in a mouse model of asthmaProstaglandins, Leukotrienes & Essential Fatty Acids, 2019
- Epidemiological profile of epilepsy in low income populationsSeizure, 2018
- LTB4 and montelukast in transplantation-related bronchiolitis obliterans in ratsJournal of Cardiothoracic Surgery, 2017
- Montelukast reduces seizures in pentylenetetrazol-kindled miceBrazilian Journal of Medical and Biological Research, 2016
- Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood–brain barrier dysfunctionNeuroscience, 2014